Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRB | P10828 | 1/20 | 0.48 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.47 |
| ▸ | SELL | P14151 | 1/20 | 0.47 |
| ▸ | SELP | P16109 | 1/20 | 0.47 |
| ▸ | MYC | P01106 | 2/20 | 0.42 |
| ▸ | MCL1 | Q07820 | 3/20 | 0.42 |
| ▸ | CA9 | Q16790 | 4/20 | 0.41 |
| ▸ | CA12 | O43570 | 3/20 | 0.41 |
| ▸ | CA1 | P00915 | 3/20 | 0.41 |
| ▸ | CA2 | P00918 | 3/20 | 0.41 |
| ▸ | CA7 | P43166 | 3/20 | 0.41 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.41 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | PRKCI | P41743 | 1/20 | 0.41 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.40 |
| ▸ | CTSB | P07858 | 1/20 | 0.40 |
| ▸ | ELANE | P08246 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7147157 | 0.88 | SELL (0.50) | THRBCSNK2A1SELLSELPMYC | |
| SCHEMBL7308758 | 0.82 | CSNK2A1 (0.46) | THRBCSNK2A1SELLSELPMYC | |
| SCHEMBL7861237 | 0.82 | HAAO (0.41) | THRBMYCMCL1ALDH1A1PTGS2 | |
| SCHEMBL2990397 | 0.81 | THRB (0.58) | THRBCA9CA12CA1CA2 | |
| SCHEMBL29282585 | 0.79 | AKR1C3 (0.50) | CSNK2A1SELLSELPCA9CA12 | |
| SCHEMBL21408388 | 0.79 | CA12 (0.55) | CSNK2A1SELLSELPMYCMCL1 | |
| SCHEMBL27663539 | 0.79 | CYP1A2 (0.42) | CSNK2A1MYCALDH1A1TSHRCYP1A2 | |
| SCHEMBL317575 | 0.79 | SELL (0.54) | THRBCSNK2A1SELLSELPMYC | |
| SCHEMBL30443442 | 0.79 | SELL (0.54) | THRBCSNK2A1SELLSELPMYC | |
| SCHEMBL30589153 | 0.77 | SELL (0.64) | THRBCSNK2A1SELLSELPMYC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1340744-B1 | Hiv protease inhibitors | AGOURON PHARMA (US) | 2007-05-23 | — | — | EP | disclosed |
| CN-1195737-C | HIV proteinase inhibitor | AGOURON PHARMA (US) | 2005-04-06 | — | — | CN | disclosed |
| EP-0889036-B1 | HIV protease inhibitors | AGOURON PHARMA (US) | 2004-12-29 | — | — | EP | disclosed |
| US-20030216569-A1 | Method of making HIV protease inhibitors | DRESSMAN BRUCE A (US) | 2003-11-20 | — | — | US | disclosed |
| EP-1340744-A2 | Hiv protease inhibitors | Agouron Pharmaceuticals, Inc. (US) | 2003-09-03 | — | — | EP | disclosed |
| US-6525215-B2 | As antiviral agents suitable for therapy of patients or hosts infected with the HIV virus, which is known to cause AIDS | AGOURON PHARMACEUTICALS, INC. | 2003-02-25 | — | — | US | disclosed |
| US-20020077338-A1 | HIV protease inhibitors | DRESSMAN BRUCE A (US) | 2002-06-20 | — | — | US | disclosed |
| US-6271235-B1 | VIRICIDE | AGOURON PHARMACEUTICALS, INC. | 2001-08-07 | — | — | US | disclosed |
| US-6162812-A | Pharmaceutical compositions containing HIV protease inhibitors and methods of their use | AGOURON PHARMACEUTICALS, INC. (US) | 2000-12-19 | — | — | US | disclosed |
| CN-1262272-A | HIV proteinase inhibitor | AGOURON PHARMA (US) | 2000-08-09 | — | — | CN | disclosed |
| US-5837710-A | HIV protease inhibitors | AGOURON PHARMACEUTICALS, INC. | 1998-11-17 | — | — | US | disclosed |
| US-5834467-A | AIDS TREATMENT; VIRICIDES | AGOURON PHARMACEUTICALS, INC. | 1998-11-10 | — | — | US | disclosed |
| US-5827859-A | ADMINISTERED TO TREAT AIDS; VIRICIDES | AGOURON PHARMACEUTICALS, INC. | 1998-10-27 | — | — | US | disclosed |
| US-5827858-A | ADMINISTERED TO TREAT AIDS | AGOURON PHARMACEUTICALS, INC. | 1998-10-27 | — | — | US | disclosed |
| US-5827891-A | FOR TREATMENT OF AIDS, BLOCKING REPLICATION OF HIV VIRUS | AGOURON PHARMACEUTICALS, INC. | 1998-10-27 | — | — | US | disclosed |
| US-5824688-A | HIV protease inhibitors | AGOURON PHARMACEUTICALS, INC. | 1998-10-20 | — | — | US | disclosed |
| CN-1131942-A | HIV protease inhibitors | AGOURON PHARMACEUTICALS INS (US) | 1996-09-25 | — | — | CN | disclosed |
| EP-0722439-A1 | HIV PROTEASE INHIBITORS | AGOURON PHARMACEUTICALS, INC. (US) | 1996-07-24 | — | — | EP | disclosed |
| US-5484926-A | VIRICIDES AND ENZYME INHIBITORS | AGOURON PHARMACEUTICALS, INC. (US) | 1996-01-16 | — | — | US | disclosed |
| WO-1995009843-A1 | HIV PROTEASE INHIBITORS | AGOURON PHARMACEUTICALS, INC. (US) | 1995-04-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020077338-A1 | HIV protease inhibitors | PREP, PRSS1, SERPINB1 | THRB 4718/4885CSNK2A1 3866/4885SELL 4369/4885 |
| US-20030216569-A1 | Method of making HIV protease inhibitors | SERPINB1, PRSS1, PREP | THRB 4715/4885CSNK2A1 3620/4885SELL 4437/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.